Oscotec plans to transfer acute myeloid leukemia treatment technology to global pharmaceutical companies
New drug developing company Oscotec announced that the anti-cancer effects of next generation acute myeloid leukemia therapeutic drug candidate 'G-749' was published in the world's leading research journal in the field of blood 'Blood', February issue online edition.
According to the company, th...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
